Search | Médecins Sans Frontières Access Campaign

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

Pandemic prevention, preparedness and response

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action

5 results found
There is 1 active filter
Clear all filters
stavudine

5 results found

Letter |

14 December 2011

Joint Letter to Bill & Melinda Gates Foundation on Clinical Trial Comparing Stavudine and Tenofovir

Tags HIV/AIDS antiretroviral medicinesstavudinetenofovir Bill & Melinda Gates Foundation

Research article |

01 March 2011

Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years

Tags HIV/AIDS HIV/AIDS stavudinetenofovirzidovudine Lesotho

Press release |

09 March 2010

AIDS Care Gap between Europe and Southern Countries Risks Becoming a Chasm

Tags HIV/AIDS HIV/AIDS antiretroviral medicinesstavudine universal access PEPFARWorld Health Organization

Letter |

11 November 2005

Letter to BMS. Access to staduvine

Tags HIV/AIDSIntellectual property and trade stavudine Bristol-Myers Squibb China

Research article |

03 July 2004

Lancet: Effectiveness and safety of a generic FDC of NVP, d4T, 3TC, in HIV-1-infected adults in Cameroon

Tags HIV/AIDS HIV/AIDS antiretroviral medicinesFDCslamivudinenevirapinestavudine Cameroon